Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 3
2022 1
2023 1
2024 4
2025 6
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Safety and use of IBD therapies during pregnancy and lactation.
Rabinowitz LG, Gade A, Deyhim T, Feuerstein JD. Rabinowitz LG, et al. Expert Rev Gastroenterol Hepatol. 2026 Feb;20(2):81-92. doi: 10.1080/17474124.2026.2615447. Epub 2026 Jan 13. Expert Rev Gastroenterol Hepatol. 2026. PMID: 41520241 Review.
Optimal management of IBD in pregnancy ideally starts before conception, with a goal of at least 3 months of steroid-free remission. ...AREAS COVERED: In this review, we discuss latest evidence on the safety and efficacy of available IBD therapies during conc …
Optimal management of IBD in pregnancy ideally starts before conception, with a goal of at least 3 months of steroid-free remi …
New drugs for the treatment of IBD during conception, pregnancy, and lactation.
Pugliese D, Privitera G, Gisbert JP, Chaparro M. Pugliese D, et al. Dig Liver Dis. 2024 Feb;56(2):235-241. doi: 10.1016/j.dld.2023.08.054. Epub 2023 Sep 15. Dig Liver Dis. 2024. PMID: 37718225 Review.
Thus, women can be exposed to different drugs during conception, pregnancy, and lactation with potentially harmful effects on the mother, foetus, or nursing infant. ...Currently, the decision to interrupt or maintain these treatments is up to physicians' judgement on a cas …
Thus, women can be exposed to different drugs during conception, pregnancy, and lactation with potentially harmful effects on the mot …
Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease.
Wieringa JW, van der Woude CJ. Wieringa JW, et al. Best Pract Res Clin Gastroenterol. 2020 Feb-Apr;44-45:101665. doi: 10.1016/j.bpg.2019.101665. Epub 2019 Dec 28. Best Pract Res Clin Gastroenterol. 2020. PMID: 32359679 Review.
Current guidelines advise to maintain immunomodulators and biologicals in pregnant patients because relapse of inflammatory bowel is associated with unfavourable pregnancy outcome. With the exception of Methotrexate, IBD therapy seems not to be related to an increas …
Current guidelines advise to maintain immunomodulators and biologicals in pregnant patients because relapse of inflammatory bowel is associa …
Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice.
Gisbert JP, Chaparro M. Gisbert JP, et al. Inflamm Bowel Dis. 2026 Apr 1;32(4):775-802. doi: 10.1093/ibd/izaf273. Inflamm Bowel Dis. 2026. PMID: 41428330 Review.
Janus kinase (JAK) inhibitors are being increasingly used in inflammatory bowel diseases (IBDs). ...Extended induction can benefit patients with partial response. Real-world data support the use of JAK inhibitors in pediatric and older ad …
Janus kinase (JAK) inhibitors are being increasingly used in inflammatory bowel diseases (IBDs). ...Extended ind …
JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications.
Agrawal M, Kim ES, Colombel JF. Agrawal M, et al. J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S755-S760. doi: 10.1093/ecco-jcc/jjaa017. J Crohns Colitis. 2020. PMID: 32006031 Free PMC article. Review.
Janus kinase inhibitors [JAKi] are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors, and are increasingly being used in the treatment of immune-mediated diseases. ...Considerations such as …
Janus kinase inhibitors [JAKi] are a new class of small molecule drugs that modulate inflammatory pathways by blocking …
Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs.
Mahadevan U, Chaparro M, Segovia M, Guo X, Kulisek N, Wu J, Vranic I, Diehl A, Kavanaugh A, Dubinsky M. Mahadevan U, et al. Am J Gastroenterol. 2026 Feb 1;121(2):549-553. doi: 10.14309/ajg.0000000000003774. Epub 2025 Sep 26. Am J Gastroenterol. 2026. PMID: 41002213 Free PMC article.
INTRODUCTION: This analysis reports updated pregnancy outcomes after tofacitinib exposure in patients with immune-mediated diseases. METHODS: Pregnancy/partner pregnancy cases from interventional studies were identified in Pfizer safety database through March …
INTRODUCTION: This analysis reports updated pregnancy outcomes after tofacitinib exposure in patients with immune-mediated diseases. …
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.
Liu E, Aslam N, Nigam G, Limdi JK. Liu E, et al. Drugs Context. 2022 Apr 8;11:2021-11-4. doi: 10.7573/dic.2021-11-4. eCollection 2022. Drugs Context. 2022. PMID: 35462642 Free PMC article. Review.
Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the National Institute for Health and Care Excellence (NICE) for use in moderately-to-severely active UC after intolerance, inadequate response, or loss …
Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the National …
Upadacitinib as Rescue Therapy in a Pregnant Patient With IBD.
Geeganage G, Flynn DJ, Martinez S, Wang MJ, Spiel M, Rabinowitz LG, Feuerstein JD. Geeganage G, et al. ACG Case Rep J. 2025 May 14;12(5):e01701. doi: 10.14309/crj.0000000000001701. eCollection 2025 May. ACG Case Rep J. 2025. PMID: 40370416 Free PMC article.
Upadacitinib is an oral Janus kinase inhibitor approved to treat moderate-to-severe ulcerative colitis. Studies have shown that upadacitinib is highly effective, though use has been limited in certain populations due to concerns of side effects. ...Additional …
Upadacitinib is an oral Janus kinase inhibitor approved to treat moderate-to-severe ulcerative colitis. Studies have sh …
Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child.
Mitrova K, Kostrejova M, Zdychyncova K, Lukas M, Duricova D. Mitrova K, et al. J Crohns Colitis. 2025 Apr 4;19(4):jjaf049. doi: 10.1093/ecco-jcc/jjaf049. J Crohns Colitis. 2025. PMID: 40127036 Free article.
BACKGROUND AND AIMS: Janus kinase (JAK) inhibitors, such as tofacitinib, are potent anti-inflammatory agents used in the treatment of ulcerative colitis (UC). ...Further research is needed to fully understand the long-term implications of JAK …
BACKGROUND AND AIMS: Janus kinase (JAK) inhibitors, such as tofacitinib, are potent anti-inflammatory agents use …
19 results